Jaguar Health Files New $75M Shelf, Replacing 2024 Registration
JAGX is trading near its 52-week low of $2.15 (0.5% below the low) on light trading volume (0.1× avg).
Summary
Jaguar Health registered a new $75 million shelf ($41.6M carried over from its 2024 shelf, $33.4M newly registered). No shares were sold — but with a going concern warning and a dilution vote pending, this is the capacity for more issuance.
Key Events · Financing and Capital Events · JAGX
-
New $75M Universal Shelf Filed
Form S-3 registers up to $75,000,000 of common stock, preferred stock, warrants, subscription rights and units for sale from time to time; no securities have been sold under it.
-
Most Capacity Is Carried-Over, Not New
$41,559,118.01 is unsold capacity rolled forward from the 2024 shelf under Rule 415(a)(6); only $33,440,881.99 is newly registered, for a $2,909.36 fee.
-
No Longer Bound by I.B.6 Cap
The filing states the company is no longer subject to the General Instruction I.B.6 one-third public float offering limitation as of the prospectus date, removing a ceiling on how much it can sell.
-
Context: Going Concern and Dilution Vote
Follows the Q2 2026 10-Q going concern warning ($3.8M cash, $4.1M net loss) and a definitive proxy for the October 23 special meeting seeking approval for up to 92.9% dilution and a reverse split.
Analysis · JAGX · Life Sciences
This is permission to sell, not a sale: $75,000,000 of common stock, preferred stock, warrants, rights and units registered for sale 'from time to time,' of which $41,559,118.01 is unsold capacity carried over from the April 2024 shelf and $33,440,881.99 is newly registered. Nothing has been issued and no proceeds have been received — each actual sale needs its own prospectus supplement. What matters is the backdrop: the Q2 2026 10-Q carried a going concern warning with $3.8M of cash, and the definitive proxy for the October 23 special meeting seeks approval for up to 92.9% dilution through CVP debt/preferred exchanges and a reverse split. A fresh shelf on top of that is the machinery for more equity issuance into a stock trading near its 52-week low, so existing holders should expect further dilution rather than treat this as neutral paperwork.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 30.5% of the 1494 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.03%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $2.15 to $1,118.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.